menu
    • menu
    [{"orgOrder":0,"company":"DP Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"DPT0218","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"DP Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Not Applicable"},{"orgOrder":0,"company":"DP Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"DPT0416","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"DP Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Not Applicable"},{"orgOrder":0,"company":"DP Technology","sponsor":"Lepu Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"DP Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"DP Technology \/ Lepu Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"DP Technology \/ Lepu Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by DP Technology

    Menu

    DP Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DP Technology

                            China arrow
                            VMX
                            Not Confirmed

                            DP Technology

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lepu Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            DP Technology Collaborates with Lepu Biopharma to Boost ADC Drug Innovation

                            Details : The partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform and advancing the candidate ADC to the clinical stage.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lepu Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DP Technology

                            China arrow
                            VMX
                            Not Confirmed

                            DP Technology

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPT0416

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            DP Technology Nominates CNS-Penetrable LP-PLA2 Inhibitor For Alzheimer's Disease

                            Details : DPT0416 is a novel CNS penetrable small molecule targeting Lp-PLA2, being investigated for the treatment of Alzheimer's disease (AD).

                            Brand Name : DPT0416

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 08, 2024

                            Lead Product(s) : DPT0416

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DP Technology

                            China arrow
                            VMX
                            Not Confirmed

                            DP Technology

                            China arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPT0218

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            DP Technology Nominates Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor

                            Details : DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor. It is being evaluated in preclinical studies for the treatment of Inflammatory Bowel Disease & Atopic Dermatitis.

                            Brand Name : DPT0218

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 30, 2024

                            Lead Product(s) : DPT0218

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth